The Main Reason Behind Buying UnitedHealth Before July 16

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) carries the highest conviction among managed care names heading into the company’s July 16 earnings report, and the setup is doing the talking. Shares of UNH last traded around $430.72 on July 9, sitting on a more than 28% year-to-date gain and a more than 42% one-year return. The repricing thesis showed up once in Q1 and is set up to repeat next Thursday.

The Repricing Is Working and the Q1 Report Proved It

Q1 2026 was the inflection. UNH delivered adjusted EPS of $7.23 versus a $6.60 consensus, a 9.55% beat, while the medical care ratio improved 90 basis points to 83.9%. Operating cash flow jumped to $8.9 billion, up 63.34% year over year. That is disciplined pricing hitting the P&L, exactly the signal CEO Stephen Hemsley was hired back to produce.

Guidance Was Raised and the Valuation Is Reasonable

Management pushed 2026 adjusted EPS guidance to greater than $18.25 per share, above the prior above-$17.75 mark. That works out to roughly 23 times forward earnings, with the analyst target at $418.04 and 23 buy or strong-buy ratings stacked against a single sell. Polymarket is currently pricing a 71% probability of a Q2 beat.

The Retirement Investor’s Cash Machine

For an income-focused retiree, the capital return schedule is the prize. UNH plans roughly $8.0 billion in dividends and $2.5 billion in buybacks in 2026, with a $2 billion buyback tranche completed by end of Q2. The yield sits at 2.15% on an $8.84 annual payout. History says beats get paid: The Q1 report produced a 6.96% same-day gain and a 10.54% 30-day return, outrunning both the S&P 500 and the Nasdaq 100. If you want the Buffett-style approach to blue-chip income, our Never Touch the Principal framework is built around exactly these kinds of compounders.

Why UNH Beats the Obvious Alternatives

Peers are still climbing out of the same cost-trend crisis. Humana (NYSE:HUM) is guiding FY 2026 adjusted EPS to at least $9.00, down from $17.14 in FY 2025, a 47% cliff driven by Star Ratings damage UNH does not carry. Elevance Health (NYSE:ELV) is recovering, but its Q4 2025 benefit expense ratio hit 93.5% and swung Health Benefits to a segment loss. UNH’s 83.9% MCR is in a different league, and its $388.9 billion market cap reflects the scale advantage.

UnitedHealth heads into the July 16 report with the strongest setup in managed care, and the data supports a constructive stance.

Contact [email protected] for any questions or corrections.